Risk factors for antepartum venous thromboembolism in pregnant people with sickle cell disease
Authors:
- Gloria F. GerberGGGloria F. Gerber
- Sacha ChoupaSCSacha Choupa
- Vinal MenonVMVinal Menon
- Nadine ShehataNSNadine Shehata
- Jayla ScottJSJayla Scott
- Macy L. E. GattiMGMacy L. E. Gatti
- Michael B. StreiffMSMichael B. Streiff
- Rakhi P. NaikRNRakhi P. Naik
- Kevin KuoKKKevin Kuo
- A. Kinga MalinowskiAMA. Kinga Malinowski
- Lydia H. PeckerLPLydia H. Pecker
- 16 November 2026
- journal article
- Published by Wiley in British Journal of Haematology
Abstract
Summary: Sickle cell disease (SCD) is a thrombophilia exacerbated by pregnancy. However, there is not strong evidence for thromboprophylaxis, perhaps because most data addressing pregnancy‐related thrombosis in SCD is limited by derivation from administrative datasets. We studied venous thromboembolism (VTE) in a retrospective cohort of pregnant people with SCD who delivered singleton pregnancies at two academic centres between 1990 and 2021. Among 289 pregnancies to 197 SCD subjects, 6% had VTE. We compared characteristics of the first study pregnancy in which a VTE occurred (cases) to the first study pregnancy in subjects without pregnancy‐related VTE (controls). Preconception complications associated with VTE were history of VTE (cases: 33% [ n = 5/15] vs. controls: 4% [ n = 7/182], p < 0.001), acute chest syndrome (ACS) (80% [ n = 12/15] vs. 37% [ n = 68/182], p = 0.001) and acute care for vaso‐occlusive crisis (VOC) in the year before pregnancy (80% [ n = 12/15] vs. 43% [ n = 70/182], p = 0.006). Prenatal complications associated with VTE were ACS (47% [ n = 7/15] vs. 10% [ n = 19/182], p < 0.001) and VOC (93% [ n = 14/15] vs. 65% [ n = 119/182], p = 0.026). Fetal outcomes associated with VTE included gestational age at delivery (median [IQR] 37.0 [34.0–38.1] weeks vs. 38.3 [36.9–39.3], p = 0.004). Studies are needed to establish interventions that attenuate VTE risk and define prophylactic anti‐coagulation parameters for this high‐risk population.Funding Information
- Foundation for Women and Girls with Blood Disorders
- National Heart, Lung, and Blood Institute (K23HL146841)
- National Heart, Lung, and Blood Institute (U01 HL156620‐01)
- National Institute of Mental Health (T32 MH 122357)
This publication has 32 references indexed in Scilit:
- Prophylactic versus on‐demand transfusion in pregnant women with sickle cell disease: A systematic review and meta‐analysis of randomised controlled trialseJHaem, 2025
- Pregnancy‐related thromboembolism in women with sickle cell disease: An analysis of National Medicaid DataAmerican Journal of Hematology, 2023
- Severe Maternal Morbidity and Mortality in Sickle Cell Disease in the National Inpatient Sample, 2012-2018JAMA Network Open, 2023
- Pregnancy outcomes in women with sickle cell disease in CaliforniaAmerican Journal of Hematology, 2023
- Venous thromboembolism in pregnant women with sickle cell disease: A retrospective database analysisThrombosis Research, 2014
- Role of the Hemostatic System on Sickle Cell Disease Pathophysiology and Potential TherapeuticsHematology/Oncology Clinics of North America, 2014
- Venous Thromboembolic Disease and PregnancyNew England Journal of Medicine, 2008
- Morbidity associated with sickle cell disease in pregnancyAmerican Journal of Obstetrics and Gynecology, 2008
- Venous thromboembolism during pregnancy and the postpartum period: Incidence, risk factors, and mortalityAmerican Journal of Obstetrics and Gynecology, 2006
- Haemostasis in Normal PregnancyThrombosis and Haemostasis, 1984